Fulvestrant in Treating Patients With Recurrent Prostate Cancer
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using
fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells.
PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with
recurrent prostate cancer.